Adamis Pharmaceuticals Announces Retirement of Richard C. Williams, Chairman of the Board
04 Marzo 2022 - 6:30AM
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), today announced
the retirement of Richard C. Williams, effective April 15, 2022.
“Dick has provided almost eight years of strategic leadership
and committed service to Adamis and has provided valuable insight
and counsel to the board as well as our staff. He has been an
exemplary leader through the challenges the company has faced and
has been fair and unwavering in his support for Adamis,” said
Adamis’ CEO and President, Dr. Dennis J. Carlo. “We admire Dick for
his work ethic and wish him all the best in his retirement.”
About Adamis
Pharmaceuticals
Adamis Pharmaceuticals Corporation is a specialty
biopharmaceutical company primarily focused on developing and
commercializing products in various therapeutic areas, including
allergy, opioid overdose, respiratory and inflammatory disease. The
company’s SYMJEPI® (epinephrine) Injection products are
approved by the FDA for use in the emergency treatment of acute
allergic reactions, including anaphylaxis. The company’s ZIMHI™
(naloxone) Injection product is approved for the treatment of
opioid overdose. Tempol is in development for the treatment of
patients with COVID-19 and a Phase 2/3 clinical trial is underway.
For additional information about Adamis Pharmaceuticals, please
visit www.adamispharmaceuticals.com and follow us
on Twitter and LinkedIn.
Contact
Adamis Investor RelationsRobert UhlManaging DirectorICR
Westwicke 619.228.5886robert.uhl@westwicke.com
Adamis Pharmaceuticals (NASDAQ:ADMP)
Gráfica de Acción Histórica
De Jun 2024 a Jul 2024
Adamis Pharmaceuticals (NASDAQ:ADMP)
Gráfica de Acción Histórica
De Jul 2023 a Jul 2024